Adamas Pharmaceuticals Inc (ADMS) Insider Jennifer J. Rhodes Sells 440 Shares
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) insider Jennifer J. Rhodes sold 440 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $32.30, for a total value of $14,212.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Adamas Pharmaceuticals Inc (ADMS) traded up $0.33 on Thursday, hitting $32.23. The stock had a trading volume of 797,600 shares, compared to its average volume of 550,897. Adamas Pharmaceuticals Inc has a 12 month low of $13.50 and a 12 month high of $38.22. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.03). During the same quarter in the prior year, the company earned ($0.66) earnings per share. Adamas Pharmaceuticals’s quarterly revenue was down 99.3% compared to the same quarter last year. sell-side analysts predict that Adamas Pharmaceuticals Inc will post -3.84 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Adamas Pharmaceuticals in the third quarter valued at approximately $110,000. Quantbot Technologies LP bought a new stake in shares of Adamas Pharmaceuticals in the third quarter valued at approximately $119,000. Tower Research Capital LLC TRC bought a new stake in shares of Adamas Pharmaceuticals in the second quarter valued at approximately $109,000. Sei Investments Co. boosted its position in shares of Adamas Pharmaceuticals by 1,105.0% in the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after acquiring an additional 8,033 shares during the period. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Adamas Pharmaceuticals in the second quarter valued at approximately $184,000. 79.40% of the stock is owned by institutional investors.
Several equities analysts have commented on ADMS shares. Northland Securities started coverage on Adamas Pharmaceuticals in a report on Wednesday, November 29th. They set an “outperform” rating on the stock. BidaskClub downgraded Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 14th. Noble Financial reiterated a “buy” rating and set a $33.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, September 29th. Mizuho reiterated a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. Finally, Piper Jaffray Companies set a $52.00 price target on Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Adamas Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $45.67.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.